Objective. To evaluate the progression of erosions and joint space narrowing (JSN) in feet and hands in the U-Act-Early trial.
Introduction
In RA, structural joint damage as a consequence of synovitis is commonly seen [1] . Typically bones are affected, resulting in erosions and loss of cartilage, leading to joint space narrowing (JSN), which eventually causes joint deformities and functional impairments if joint inflammation is not targeted adequately. With the development of conventional synthetic (csDMARDs) and biologic DMARDs (bDMARDs) and the implementation of treat-to-target approaches, aiming for clinical remission, a remarkable gain is made in preventing joint damage and therefore in improving the long-term outcome of RA patients [2] . As smaller joints are more frequently affected in early RA, radiographs of both hands and feet are the current standard to assess structural changes, and radiography is therefore considered to be a pivotal tool for assessing therapeutic efficacy.
International recommendations/guidelines for the management of RA recommend that a csDMARD, preferably MTX, should be (part of) the first treatment strategy and that, if the treatment target is not achieved, adding a bDMARD may be considered [3, 4] . To date, MTX remains the anchor drug in treating newly diagnosed RA because of its beneficial efficacysafety and cost-effectiveness ratios [3] . Nevertheless, in about 30% of the patients achieving the treatment target on this drug, progression of radiographic changes is still observed as a result of subclinical inflammation [5, 6] . Starting therapy with a bDMARD, with or without MTX, may improve the clinical outcome by more effectively reducing disease activity. Tapering and finally discontinuing the biological once remission is achieved might minimize health care costs and the number of patients who are over-treated, as some would have achieved the treatment target also with MTX therapy alone.
In the 2-year, multicentre, phase 3, double-blind, placebo-controlled U-Act-Early strategy trial (ClinicalTrials.gov identifier NCT01034137), DMARD-naïve patients with early RA were randomized to start treatment with tocilizumab, step-up MTX or a combination of the two and were treated to target until sustained remission (defined as DAS28 <2.6 with four or fewer swollen joints for 524 weeks) was achieved. Clinical efficacy and safety data have been reported previously in which significantly less joint damage, as assessed by the Sharpvan der Heijde score (SHS) [7] , was found in both tocilizumab arms when compared with the MTX arm [8] . This article reports in more detail the effect of the treatment strategies on the progression of erosions and JSN separately, according to the SHS method, in the feet and hands. In addition, we evaluated if there was an association between progression of joint damage and the three therapeutic strategies and whether this association was in part independent from suppression of disease activity, as reported in literature for other biologicals [912] .
Methods

Study design and population
Patients with newly diagnosed RA visiting one of the 21 participating rheumatology departments in the Netherlands were invited to participate in the U-Act-Early strategy trial. To be eligible, patients had to be >18 years, be DMARDnaïve, meet the 1987 ACR or the 2010 ACR/EULAR classification criteria for RA, have active disease (DAS28 52.6), and have been diagnosed with RA within the previous 12 months before inclusion. Patients were randomized (1:1:1) in permuted blocks of six, stratified by centre and baseline DAS28 (i.e. DAS28 <5.1 or 55.1) to initiate tocilizumab plus MTX, or tocilizumab plus placebo-MTX, or MTX plus placebo-tocilizumab therapy and were treated to target until sustained remission was achieved. Placebo/ tocilizumab (8 mg/kg) was given every 4 weeks intravenously up to a maximum of 800 mg per dose. MTX (orally) was started at 10 mg/week and increased stepwise with 5 mg every 4 weeks to 30 mg/week until remission or the maximum tolerable dose was achieved; the same scheme was used for placebo-MTX. If remission was not achieved with the initial therapy, HCQ was added as a second step in the initial treatment strategies. Hereafter, if the target still was not reached, the initial strategies ended and the subsequent treatment strategy was started. Patients randomized to the tocilizumab or MTX arm then discontinued the placebo and switched to tocilizumab plus MTX combination therapy; those who initially started with the combination switched to the standard of care (e.g. MTX combined with a TNF inhibitor). If the treatment target, sustained remission, was achieved, medication was tapered stepwise and finally stopped. First placebo/MTX was tapered with 5 mg every 4 weeks down to 10 mg/week and then discontinued; thereafter the dose of placebo/tocilizumab was decreased to 4 mg/kg and stopped after 3 months. Sustained drug-free remission (sDFR) was achieved when patients were drug-free for 512 weeks while in sustained remission (one visit with low disease activity (DAS28 43.2) was allowed). A detailed description of the study design, including treatment strategies, has been previously reported [8] . The medical ethics research committee of the University Medical Centre Utrecht approved the study for all participating hospitals. All patients signed informed consent before entering the study.
Sharpvan der Heijde score
The SHS was used to evaluate progression of radiographic joint damage. Radiographs of the hands (including wrists) and feet were taken at baseline and after 52 and 104 weeks. Sixteen and six areas were considered for assessing erosions and JSN in both hands and feet, respectively. The maximum erosion score of hands and wrists is 160 and of the feet it is 120 (maximum total erosion score 280). The maximum JSN score of hands and wrists is 120 and of the feet it is 48 (maximum total JSN score 168). The sum of the erosion and JSN scores is the total SHS (maximum 448). All radiographs were scored centrally in chronological order by a blinded (experienced and trained) professional reader.
Automated joint space width quantification
To assess the JSN of the hands with a more sensitive method, we used an automated method for measuring joint space width (JSW) as previously described by Huo et al. [13, 14] . Briefly, this computerized joint space quantification method measures in millimetres the JSW of PIP joints, MCP joints and joints of the wrist, consisting of the trapezium-trapezoides-navicular, carpo-navicular-lunate and the radiocarpal joints, bilaterally. After the joint margins were automatically delineated, the average Euclidean distance between the upper and lower margin was calculated within the middle 60% of the joint span and the JSW was determined for each joint separately. The average JSW scores of all the joints (i.e. PIP, MCP and wrist joints) of both extremities were used to calculate the total JSW hand score. The automated joint space quantification method has been proven effective in measuring radiographic changes in the hands within DMARD-naïve patients with early RA [15] ; JSW quantification of the foot joints with this method has to date not yet been developed.
Statistical analyses
Analyses were performed based on the intention-to-treat population: those who were randomized and received at least one dose of medication. Radiographic joint scores are described as mean (S.D.) and median (interquartile range, IQR). For between-group comparisons at followup, we calculated changes from baseline in total SHS, including erosion and JSN scores and both subscores separately in the hands and feet, and analysed these using a two-sided stratified non-parametric MannWhitney (Van Elteren) test, controlling for the two randomization stratification factors, baseline DAS28 (i.e. DAS28 <5.1 or 55.1) and centre. The same analyses were performed for JSN scores of the hand as measured by the computerized JSW quantification method. In addition, the proportions of patients without radiographic progression (change from baseline 40) were analysed using a Pearson chi-square test. To evaluate if the progression in radiographic joint damage within the strategy arms over time was associated with disease activity (as expected) and whether an effect on progression of joint damage of the treatment strategies remained after correction for disease activity, we performed longitudinal regression analysis (mixed model analysis using a random intercept). The dependent variable in this analysis was the delta (Á) SHS over time (i.e. change from baseline to week 52 and change from week 52 to 104) and baseline DAS28, baseline SHS and treatment strategy were used as timeindependent covariates and time (week after baseline) and the average disease activity (mean DAS28) during a progression period as time-varying covariates. These longitudinal regression analyses were also performed for the JSN and erosion scores separately. Furthermore, to evaluate the effect of tapering and discontinuing therapy as defined in the design of this study, we compared the change in SHS (as well as for erosion and JSN) in longitudinal regression analyses between patients achieving sDFR vs those achieving the treatment target, sustained remission (i.e. not able to discontinue medication). Missing radiograph scores were imputed using data from the withdrawal visit with a maximum time window of 180 days. All analyses were performed based on the entire treatment strategy, thus including the addition of HCQ and switching from placebo to active therapy (in the tocilizumab and MTX arms). Patients switching to the standard of care according to protocol were no longer followed within the study. A P < 0.05 (two tailed) was considered statistically significant; R version 3.4.0 was used for data analyses.
Results
Patient population
Of the recruited patients, 317 were eligible to participate in the U-Act-Early study (tocilizumab plus MTX arm, 106; tocilizumab arm, 103; MTX arm, 108); only minor differences in the baseline characteristics between the three strategy arms were noted [8] . The majority of the study population was female (67%), was seropositive for RF (72%) or anti-CCP (70%), had on average high disease activity [mean (S.D.) DAS28 5.2 (1.1) at baseline with a median (IQR) symptom duration of 26 (1643) days], and had none or minor radiographic joint damage [median (IQR) SHS 0 (01)]. In total, radiographs were obtained of 97 (92%), 92 (89%) and 91 (84%) patients at week 52 and of 76 (72%), 75 (73%) and 75 (69%) patients at week 104 in the tocilizumab plus MTX, tocilizumab and MTX arms, respectively.
Patient disposition
After 52 weeks of treatment, 95% of the patients in the tocilizumab plus MTX-and 92% in the tocilizumab-based treatment strategies were still on the initial treatment regimen; in the MTX arm this proportion was 61% (Fig. 1) . The proportions receiving or having received HCQ in addition, as part of the initial treatment strategy, during the first 52 weeks of the study were 30% in the tocilizumab plus MTX arm, 21% in the tocilizumab arm and 62% in the MTX arm. During the second year, the proportions of patients within the treatment strategies who received or had received HCQ further increased only marginally (tocilizumab plus MTX, 37%; tocilizumab, 22%; MTX, 66%). After 104 weeks, the large majority of the patients in the tocilizumab-based strategies still remained on the initial treatment regimen (tocilizumab plus MTX, 92%; tocilizumab, 87%), in contrast to the MTX strategy arm (54%).
Radiographic joint damage
The cumulative frequencies of changes from baseline to weeks 52 and 104 in the SHS are shown in Fig. 2 . In the previously published results of U-Act-Early it was reported that changes from baseline in radiographic joint damage, as evaluated by the SHS, were significantly lower in the tocilizumab plus MTX arm compared with the MTX arm after 52 weeks (P = 0.016; Table 1 ) [8] . After 104 weeks, less progression in joint damage was noted in both tocilizumab arms (tocilizumab plus MTX, P = 0.021; tocilizumab, P = 0.038) when compared with the MTX arm. In the present study, when evaluating the changes of the JSN and erosion scores separately, no significant differences were found in the JSN scores at week 52 (P 5 0.09) or 104 (P 5 0.25) between the three treatment arms. For erosions, the changes from baseline to week 52 did not statistically differ between the treatment arms (P 5 0.20), but after 104 weeks, significantly lower erosion progression scores were found in the tocilizumab plus MTX (P = 0.016) and tocilizumab arm (P = 0.023) when compared with the MTX arm. Figure 3 shows proportions of patients without radiographic progression (change from baseline 40).
In those assigned to initiate tocilizumab plus MTX, the proportions of patients without progression in SHS were significantly higher at weeks 52 (84% vs 67%, P = 0.009) and 104 (74% vs 52%, P = 0.006), compared with those assigned to the MTX strategy; for the tocilizumab strategy, the comparisons with the MTX strategy were not statistically significant (77%, P = 0.13 and 65%, P = 0.10, respectively). The proportion of patients without progression in erosions was higher in the tocilizumab-based strategies at week 52 (tocilizumab plus MTX: 87%, P = 0.038; tocilizumab: 81%, P = 0.29) and at week 104 (tocilizumab plus MTX: 85%, P < 0.001; tocilizumab: 77%, P = 0.028), compared with the MTX strategy (74% and 60%, respectively). No significant differences were found between the strategies in the proportion of patients without progression in JSN (P 5 0.22). When analysing the changes from baseline in JSN and erosion scores of both the hands and feet separately, no significant differences were found between the strategies in both extremities in JSN scores during the trial period (P 5 0.12; Table 2 ). Also, no significant differences were noted in the erosion score of hands during follow-up (P 5 0.11). After 104 weeks, significantly less progression of erosions was found in the feet in both tocilizumab arms (tocilizumab plus MTX, P = 0.046; tocilizumab, P = 0.022) compared with in the MTX arm; this was not significant at week 52 (P 5 0.36).
Joint damage in sustained drug-free remission It was previously reported that a significantly higher proportion of patients who initiated tocilizumab plus MTX (37/106, 35%) or tocilizumab (28/103, 27%) therapy achieved sDFR when compared with those initiating MTX (12/108, 11%) therapy (tocilizumab plus MTX vs MTX: P < 0.001; tocilizumab vs MTX: P = 0.004) [8] . When performing longitudinal analyses to evaluate the radiographic progression in those achieving sDFR vs those achieving sustained remission (i.e. not able to discontinue medication), significantly lower SHS (mean À0.75, 95% CI: À1.38, À1.11; P = 0.022) was found in patients achieving sDFR indicating less progression. These differences were also significant for JSN (mean À0.38, 95% CI: À0.67, 0.08; P = 0.012 vs sustained remission) but not for erosion (mean À0.44, 95% CI: À1.05, 0.17; P = 0.16 vs sustained remission) scores. No treatment-dependent differences of this effect were observed (P 5 0.08).
Association of radiographic progression with disease activity
In the longitudinal analysis we found less progression in joint damage over time in the tocilizumab strategies (tocilizumab plus MTX: mean SHS À0.71, 95% CI: À0.33, À1.36; P = 0.030; tocilizumab: mean SHS À0.53, 95% CI: À1.18, 0.12; P = 0.12) compared with MTX strategy, corrected for baseline DAS28 and SHS and time (week of visit). After correcting also for DAS28 score over time, the effect of the tocilizumab strategies on progression of joint damage decreased slightly (tocilizumab plus MTX: mean SHS À0.55, 95% CI: À1.22, 0.11; P = 0.10 vs MTX; tocilizumab: mean SHS À0.39, 95% CI: À1.05, 0.28; P = 0.26 vs MTX) but was no longer statistically significant. As expected, we found that higher disease activity over time was significantly related to higher progression of joint damage (mean DAS28 0.29, 95% CI: TCZ: tocilizumab.
0.05, 0.52; P = 0.015). As tocilizumab is known to affect acute-phase proteins [16, 17] , we repeated the analysis using the clinical disease activity index (CDAI) as disease activity measure, which is a composite score not containing inflammatory markers, and found similar results (tocilizumab plus MTX: mean CDAI À0.61, 95% CI: À0.01, 0.63; P = 0.09 vs MTX; tocilizumab: mean CDAI À0.43, 95% CI: À1.14, 0.28; P = 0.23 vs MTX) confirming the (non-statistically significant) effect of tocilizumab on joint damage. As significant differences were found between the strategy arms during follow-up in erosions but not in JSN, these analyses were also applied to both subscores separately. For erosions, the progression over time, corrected for disease activity, was lower (not significant) in the tocilizumab strategies (tocilizumab plus MTX: mean À0.67, 95% CI: À1.36, 0.02; P = 0.059 vs MTX; tocilizumab: mean À0.50, 95% CI: À1.18, 0.18; P = 0.15 vs MTX); for JSN, the disease activity corrected mean (95% CI) progression over time was in the tocilizumab plus MTX arm À0.27 (À0.61, 0.08) and in the tocilizumab arm 0.01 (À0.33, 0.35), both not statistically significant (P 5 0.13) when compared with the MTX arm.
Joint space quantification
The change from baseline in JSW, as measured by joint space quantification, after weeks 52 and 104 in the PIP, MCP, wrist and hand joints is shown in Table 3 . No significant differences were found between the treatment strategies in the PIP (P 5 0.21), MCP (P 5 0.18), wrist (P 5 0.53) and hand (P 5 0.21) joints during follow-up, confirming the JSN results in the hands of the SHS.
Discussion
To our knowledge, U-Act-Early is the first randomized controlled trial reporting on the 2-year progression of radiographic joint damage in DMARD-naïve patients with very early RA treated to target with a tocilizumab-based 
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Change from baseline to weeks 52 and 104. *P < 0.05 when compared with the MTX arm. All scores according to the Sharpvan der Heijde method; Erosion: erosion score; JSN: joint space narrowing score; TCZ: tocilizumab.
strategy. Previously published results show that initiation of tocilizumab therapy, with or without MTX, resulted in significantly less joint damage, as measured by the SHS, when compared with initiating step-up MTX therapy, which is the current standard for starting DMARD treatment in RA patients [8] . As an extension to the previous results, this study demonstrates an inhibiting effect of treat-to-target tocilizumab therapy on the progression of erosions, especially in the feet, preventing the development of physical impairments and therefore improving the long-term clinical outcome in these patients. When, according to current standards, treatment in newly diagnosed RA patients is started with csDMARDs in a treat-to-target approach, aiming at remission [3, 4] , subclinical inflammation is often seen in those who achieve the treatment target. MRI studies in RA patients clinically in remission on csDMARD therapy demonstrated that approximately one-third of them still showed radiographic progression, of whom 96% had signs of synovitis [5, 6] . In the present study, results (although not statistically significant) suggest a superior joint sparing effect of tocilizumab compared with that of MTX, even when corrected for disease activity, thus correcting for the faster and better clinical effect of tocilizumab, which is in line with the findings described above and with results of previous studies on other biologicals [912] . IL-6 is positively correlated with synovitis [16, 18, 19] , but also causes deterioration of bone and cartilage via several other mechanisms. First, a higher level of IL-6 increases the expression of VEGF, which as a result of angiogenesis leads to pannus formation and eventually causes cartilage damage and bone erosions [20] . Second, IL-6 stimulates osteoclastogenesis by interaction with RANK-B ligand (RANKL) [17] , and also by mechanisms independent of RANK [21] , leading to bone destruction. Third, IL-6 simulates secretion of MMPs by activating synoviocytes and chondrocytes, which causes cartilage degradation [17] . Thus, via these mechanisms, the superior joint sparing effect of tocilizumab compared with that of MTX, even if corrected for disease activity, can be explained.
In the present study, when evaluating the two subscores of the SHS separately, we found no significant differences in the progression of JSN, which we confirmed in the hand with a computerized JSW quantification method, and only the changes in erosions over 2 years were significantly different between the tocilizumab arms and the MTX arm. These results are largely in accordance with the findings of the FUNCTION study in which also more progression of erosions and JSN was observed in patients with early RA treated with MTX compared with those treated with tocilizumab plus MTX and tocilizumab. In the tocilizumab plus MTX group, erosions were signficantly less in that study at week 52 with JSN only numerically lower when compared with the MTX arm; these differences were not statistically significant after 2 years [22, 23] . As both the U-Act-Early and the FUNCTION study were not powered to analyse radiographic changes, which frequently are minimal especially in early RA patients treated to target, P-values should be interpreted with caution as lack of significance could well be due to insufficient statistical power (i.e. type II error). Nevertheless, also in established RA more joint sparing effect of tocilizumab has been demonstrated compared with that of MTX therapy supporting the effectiveness of this therapy in various patient populations [24] . As in our study erosions contributed most to the progression of joint damage measured by the SHS, we further analysed progression of erosive damage in the limbs separately and found significant differences only in the feet when comparing the tocilizumab arms with the MTX arm. Although this is the first tocilizumab trial evaluating limb specific structural joint changes, it has been shown previously that in RA patients treated with csDMARD, the long-term progression of erosions is higher in feet compared with hands or wrists [25] . An explanation of more rapid progression of erosions in the lower limb might be the different scoring ranges of the hands (range 05) and feet (range 010), that is, changes in individual joints of the feet have a greater impact on progression rates. However, the maximum theoretical score of feet is less than that of hands and wrists. Another explanation could be that joints in the feet are exposed to high weight-bearing pressures, while standing and walking, and are therefore more prone to develop structural changes when inflammation is present.
In conclusion, this study demonstrates that initiating a treat-to-target tocilizumab therapy, with or without MTX, in DMARD-naïve patients with early RA is more effective in preventing progression of erosions compared with a step-up MTX strategy. Especially in the feet we found less erosion in the tocilizumab-based strategies showing that by rapidly reducing inflammation, the functional ability can be preserved in newly diagnosed patients.
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